BCM
PACB icon

Bayesian Capital Management’s Pacific Biosciences PACB Stock Holding History

Bayesian Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-213,900
Closed -$364K – 905
2024
Q3 		$364K Buy
+213,900
New +$351K 0.04% 434
2023
Q3 		– Sell
-10,836
Closed -$144K – 909
2023
Q2 		$144K Buy
+10,836
New +$132K 0.02% 670
2019
Q2 		– Sell
-16,900
Closed -$122K – 647
2019
Q1 		$122K Sell
16,900
-16,994
-50% -$123K 0.02% 501
2018
Q4 		$251K Buy
+33,894
New +$215K 0.05% 461
2017
Q4 		– Sell
-10,200
Closed -$54K – 677
2017
Q3 		$54K Buy
+10,200
New +$43.8K 0.01% 458
2016
Q4 		– Sell
-31,510
Closed -$282K – 675
2016
Q3 		$282K Buy
31,510
+14,710
+88% +$123K 0.19% 209
2016
Q2 		$118K Buy
+16,800
New +$153K 0.07% 356

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's PACB Position: Q4 2024 in Review

Bayesian Capital Management sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 213,900 shares — an estimated $364K sold.

Bayesian Capital Management first reported a position in PACB in Q2 2016 and held it in 7 quarters. The position peaked at $364K in Q3 2024. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Bayesian Capital Management reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 213,900 Pacific Biosciences shares in Q4 2024, an estimated $364K.
  • Bayesian Capital Management first reported a position in Pacific Biosciences in Q2 2016 and held it in 7 quarters.
  • Bayesian Capital Management's Pacific Biosciences position peaked at $364K in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.